PACTR202402866059449尚未招募4 期
Efficacy and Safety of empagliflozin in patients with hepatic ascites: a randomized controlled trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- one
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •1. 18 years old or older.
- •2. Decompensated liver cirrhosis complicated with ascites.
- •3.Ability to understand and willingness to participate and sign a written informed consent document
排除标准
- •1.age under 18 years old;
- •2.History of any attack of hypoglycemia (defined as serum glucose less than 70 mg/dl) either symptomatic or a symptomatic.
- •3.vitally unstable pt
- •4.Patients who receive non-selective B-blockers.
- •5.History of recurrent urinary tract infection defined as more than 2 infections in last 6 months
- •6.Pregnancy and breast feeding
- •7.History of hypersensitivity to any SGLT2 inhibitor
- •8.Presence of hepatocellular carcinoma or any other malignancy.
- •9.eGFR below 45mL/min/1.73m2 or decrease in eGFR by >30% between screening
- •10. Patients with history of diabetes mellitus complicated with diabetic ketoacidosis (DKA) or patients have any risk factors for DKA
- •12. History of alcohol intake
研究者
相似试验
招募中
4 期
The effect of empagliflozin in patients with idiopathic edemaIdiopathic edema.Edema, unspecifiedR60.9IRCT20230314057712N1Ahvaz University of Medical Sciences70
尚未招募
3 期
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
招募中
3 期
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function testsIRCT20191209045671N3Semnan University of Medical Sciences60
尚未招募
3 期
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patientsIRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90